打开APP
userphoto
未登录

开通VIP,畅享免费电子书等14项超值服

开通VIP
ATMP - EMA Reflection Paper on Classification of Advanced Therapy Medicinal Products

Recently, the European Medicines Agency published an Reflection Paper on classification of advanced therapy medicinal products. This document is open for consultation until 31 July 2012.

Following the Regulation EC) No 1394/2007  the "Advanced Therapy Medicinal Products (ATMPs) Regulation", European Medicines Agency and European Commisison determine whether or not a given product meets the scientific criteria which define ATMPs. For clarifying the status of such a product  applicants have access to an optional procedure which is the CAT (Committee for Advanced Therapies) scientific recommendation for the classification of ATMPs. This procedure would be useful for the Agency as well as for the applicants to evaluate the status of the product.

The ATMP classification is based on the evaluation of whether a given product fulfils one of the definitions of gene therapy medicinal product (GTMP), somatic cell therapy medicinal product (sCTMP) or tissue engineered product (TEP) and whether the product fulfils the definition of a combined ATMP or not. However, it is also acknowledged that, due to the complex nature of these therapeutic products, the limited data package at an early stage of product development and the rapid evolution of science and technology, questions of borderline may arise.

The classification should help the developers to identify the applicable regulatory framework and furthermore the development path and the scientific-regulatory guidance to be followed. Amongst this, it will be helpful in the dialogue with the regulators and to determine whether, depending on the type of product, liaison with other committees such as Committee for Orphan Medicinal Products (COMP) and/or Paediatric Committee (PDCO) may be recommended to the applicant.

Please see the complete "Reflection paper on classification of advanced therapy medicinal products" with the executive summary, the discussion and the references for further information.

Please pay attention to ECAs new workshop on "GMP for Advanced Therapy Medicinal Products", on 12 October 2012 in Heidelberg, Germany.

Compiled by
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)

本站仅提供存储服务,所有内容均由用户发布,如发现有害或侵权内容,请点击举报
打开APP,阅读全文并永久保存 查看更多类似文章
猜你喜欢
类似文章
【热】打开小程序,算一算2024你的财运
20171128 ECA新闻:ATMP的GMP---EC采用新指南
Quotes of Rumi
Molecular Therapy Nucleic Acids: 一种先进治疗药物慢病毒载体在CAR-T细胞中的应用
Phase II study of fulvestrant in recurrent/me...
BS EN ISO 15848-1-2015Industrial valves-Measurement, test and qualification procedures for fugitive emissions
Hong Kong consultation hits phase 2
更多类似文章 >>
生活服务
热点新闻
分享 收藏 导长图 关注 下载文章
绑定账号成功
后续可登录账号畅享VIP特权!
如果VIP功能使用有故障,
可点击这里联系客服!

联系客服